| Name: | Bendamustine Related Compound H |
| Catalogue No. | VL1450005 |
| CAS No. | 1228551-91-4 |
| Molecular Formula | C32H41Cl3N6O4 |
| Molecular Weight | 680.07 |
| Status | In-stock |
| IUPAC Name | (4-[5-({2-[(4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoyl)oxy]ethyl}(2- chloroethyl)amino)-1-methyl-1H-benzimidazol-2-yl]butanoic acid) |
| Synonyms | Bendamustine Trichloroethyl Dimer Impurity /Bendamustine Dimer Impurity |
| Appearance | Pale Yellow to Light Beige Solid |
| Description | Bendamustine Related Compound H ( CAS No: 1228551-91-4 ) or (4-[5-({2-[(4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoyl)oxy]ethyl}(2- chloroethyl)amino)-1-methyl-1H-benzimidazol-2-yl]butanoic acid)is associate impurity of Bendamustine. Bendamustine could be a chemical compound drug indicated to be used within the treatment of chronic cancer of the blood (CLL) and indolent B-cell non-Hodgkin cancer (NHL) |
| References | “Sci-Hub | Bendamustine | 10.2165/00003495-200161050-00009.” Hkvisa.net, 2022, sci-hub.hkvisa.net/10.2165/00003495-200161050-00009. |
